Humanigen

Humanigen Cash Conversion

Delisted

The Cash Conversion Rate (OCF/Net Income) of Humanigen (HGENQ) as of Oct 12, 2026 is 108.44 %. In the previous year, Cash Conversion Rate (OCF/Net Income) was 77.77 % — a change of 39.43% (higher).

Cash Conversion

108.44 %

YoY

39.43%

Last updated:

Cash Conversion Rate (OCF/Net Income) of Humanigen is 2022 108.44 % . Cash Conversion Rate (OCF/Net Income) of Humanigen was 2021 77.77 % . It decreases by 39.43% higher compared to the previous year.

The Humanigen Cash Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion
Date
Cash Conversion
Jan 1, 2015
82.14 USD
Jan 1, 2016
77.57 USD
Jan 1, 2017
64.80 USD
Jan 1, 2018
51.75 USD
Jan 1, 2019
38.87 USD
Jan 1, 2020
78.01 USD
Jan 1, 2021
77.77 USD
Jan 1, 2022
108.44 USD
The Humanigen Cash Conversion history
YEARCash ConversionYoY
108.44 %+39.43%
77.77 %-0.30%
78.01 %+100.68%
38.87 %-24.88%
51.75 %-20.14%
64.80 %-16.46%
77.57 %-5.56%
82.14 %-13.16%
94.58 %—
Access this data via the Eulerpool API

Humanigen Stock analysis

What does Humanigen do? Humanigen Inc is a pharmaceutical company specializing in the discovery, development, and marketing of drugs, therapies, and solutions in the field of medical research. The company was originally founded in 2000 and is headquartered in Burlingame, California. One major focus of Humanigen Inc is the treatment of severe and life-threatening diseases such as cancer or HIV/AIDS that have not been sufficiently addressed by other medications. The company has developed a range of special technologies that enable it to develop innovative and effective therapies and drugs. An important aspect of Humanigen Inc's business model is collaboration with other companies, institutions, and research facilities worldwide. Through partnerships and cooperation, the company is able to cover the entire spectrum of research and development, allowing it to develop treatment options even faster and more effectively. Humanigen Inc has several different divisions and products designed for various applications. An important subsidiary of the company is the Humanigen Center for HIV Cure Research, which specifically focuses on combating HIV. There, the company works closely with scientists, researchers, and partners to develop new and innovative treatment options. Another important product of Humanigen Inc is the drug Lenzilumab. Lenzilumab is an antibody used to treat severe and life-threatening diseases such as cancer and COVID-19. Lenzilumab has shown great promise in clinical trials and could be the key to developing new and effective treatment options. In addition, Humanigen Inc has filed a variety of patents that enable it to develop new and innovative technologies in medical research. Many of these technologies are also licensed by other companies and research institutions, promoting the growth and expansion of Humanigen Inc. In recent years, the company has also placed a major focus on the field of digital technology. By utilizing big data, artificial intelligence, and other digital technologies, Humanigen Inc is able to develop new therapy options even faster and more effectively, catering specifically to the needs of patients and doctors. Overall, Humanigen Inc is an innovative and rapidly growing company focused on the development of new and effective treatment options for serious diseases. Through collaboration with other companies and institutions, the development of new technologies, and a targeted focus on the needs of patients and doctors, the company is able to respond even faster and more effectively to challenges in the field of medical research. Humanigen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Humanigen stock

Cash Conversion Rate (OCF/Net Income) of Humanigen is 108.44 % in 2022.

Cash Conversion Rate (OCF/Net Income) of Humanigen changed from 77.77 % to 108.44 %, representing a 39.43% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Rate (OCF/Net Income) Humanigen since 2006 – with annual values, charts, and detailed analysis.

Cash conversion measures how effectively net income converts to operating cash flow. Ratios above 100% indicate high-quality, cash-backed earnings.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Rate (OCF/Net Income)'s Humanigen with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Rate (OCF/Net Income)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Rate (OCF/Net Income).

Access this data via the Eulerpool API

Cash Flow — Humanigen

All Key Metrics — Humanigen